Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

Description

The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

Conditions

Sickle Cell Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

Arginine Therapy for the Treatment of Vaso-Occlusive Events in Children With Severe Sickle Cell Disease

Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

Condition
Sickle Cell Disease
Intervention / Treatment

-

Contacts and Locations

Atlanta

Children's Healthcare fo Atlanta at Hughes Spalding, Atlanta, Georgia, United States, 30303

Atlanta

Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States, 30322

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Established diagnosis of sickle cell disease--Hemoglobin SS (Hb-SS) or Sβᴼ-thalassemia
  • * 7-21 years of age
  • * Weight \>= 25kg (55lbs)
  • * Pain requiring medical care in an acute care setting (emergency department (ED), hospital ward, day hospital, clinic) requiring parenteral opioids, not attributable to non-sickle cell causes.
  • * Decision to discharge home from acute care setting.
  • * Diagnosis of sickle cell disease with any of the following types: hemoglobin SC disease (HbSC), hemoglobin beta thalassemia (Hb-Beta Thal), hemoglobin SD disease (HbSD), hemoglobin SE disease (HbSE), hemoglobin SO disease (HbSO), hemoglobin AS carrier (Hb AS)
  • * Hemoglobin less than 5 gm/dL
  • * Immediate Red cell transfusion anticipated
  • * Renal dysfunction: Creatinine \>1.0 or 2 x baseline
  • * Mental status or neurological changes
  • * Acute stroke or clinical concern for stroke
  • * Pregnancy
  • * Allergy to arginine
  • * Previous hospitalization \< 7 days
  • * Use of inhaled nitric oxide, sildenafil or arginine within the last 14 days
  • * Not an appropriate candidate in the investigator's judgement

Ages Eligible for Study

7 Years to 21 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Emory University,

Claudia Morris, MD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

2026-07